1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAA for Sickle Cell Trait

N/A

Waitlist Available

Led By Boris Stoeber

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

No Placebo-Only Group

Summary

This trial evaluates low-cost screening techniques to detect sickle cell disease, sickle cell trait, and β-thalassaemia in remote/rural settings, to reduce mortality rate and improve quality of life.

Eligible Conditions

Sickle Cell Anemia
Sickle Cell Trait
Sickle Cell-Beta Thalassemia
Beta Thalassemia
Sickle Cell Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAAExperimental Treatment6 Interventions

Around 20 participants each (in Nepal): * with the homozygous form of sickle cell disease (HbSS) * with the heterozygous form of sickle cell disease (HbAS) * with the compound heterozygous form of sickle cell disease (HbS/β-thalassemia) * with the carrier form of β-thalassemia (HbA/β-thalassemia) * with the carrier form of β-thalassemia (HbA/β-thalassemia) * without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc. Around 30 participants each (in Canada): * with the homozygous form of sickle cell disease (HbSS) * with the heterozygous form of sickle cell disease (HbAS) * without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Automated sickling test

2022

N/A

~150

Gazelle Hb Variant Test

2022

N/A

~150